ストックスクリーナーアプリを入手
12.14
0.65%
-0.08
アフターアワーズ：
12.13
-0.010
-0.08%
前日終値:
$12.22
開ける：
$12.21
24時間の取引高:
1.21M
Relative Volume:
0.67
時価総額：
$823.46M
収益：
$65,400
当期純損益:
$-46.34M
株価収益率:
-13.20
EPS:
-0.92
ネットキャッシュフロー:
$-38.74M
1週間 パフォーマンス:
-1.78%
1か月 パフォーマンス:
+33.11%
6か月 パフォーマンス:
+23.12%
1年 パフォーマンス:
+129.92%
1日の値動き範囲:
$11.88
$12.22
1週間の範囲:
$11.88
$12.99
52週間の値動き範囲:
$3.61
$13.85
CorMedix Inc Stock (CRMD) Company Profile
名前
CorMedix Inc
セクター
電話
908-517-9500
住所
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.14 | 838.31M | 65,400 | -46.34M | -38.74M | -0.92 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Leerink Partners | Outperform |
| 2025-01-13 | 開始されました | D. Boral Capital | Buy |
| 2024-08-26 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-02-17 | 開始されました | Needham | Buy |
| 2020-09-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-09-21 | 開始されました | Truist | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2019-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-12-06 | 開始されました | ROTH Capital | Buy |
| 2017-09-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-08-10 | 繰り返されました | Rodman & Renshaw | Buy |
| 2017-05-05 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-11-11 | 繰り返されました | FBR & Co. | Outperform |
| 2016-03-17 | 繰り返されました | FBR Capital | Outperform |
| 2016-03-03 | 開始されました | FBR Capital | Outperform |
| 2015-11-16 | 繰り返されました | ROTH Capital | Neutral |
| 2015-10-29 | 繰り返されました | ROTH Capital | Neutral |
| 2015-05-06 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 繰り返されました | ROTH Capital | Buy |
| 2011-10-03 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
CorMedix Inc (CRMD) 最新ニュース
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference - The Manila Times
CorMedix Brings Latest Therapeutic Developments to Jefferies Healthcare Conference 2025 - Stock Titan
(CRMD) Trading Advice - news.stocktradersdaily.com
CorMedix at RBC Capital Markets: Strategic Expansion and Growth - Investing.com Australia
CorMedix at RBC Capital Markets: Strategic Expansion and Growth By Investing.com - Investing.com Nigeria
CorMedix Inc. to Participate in the RBC Global Healthcare Conference - The Manila Times
CorMedix Inc. to Participate in RBC Capital Markets Global Healthcare Conference on May 21, 2025 - Nasdaq
Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week - Stock Titan
CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement - ACCESS Newswire
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock - Yahoo Finance
Market Highlights: CorMedix Inc (CRMD) Ends on a High Note at 12.03 - DWinneX
CorMedix Inc. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
CorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
Cormedix anticipates Q2 revenue at high end of $23M-$31M range with inpatient growth accelerating - MSN
Cormedix (CRMD) Receives a Buy from RBC Capital - The Globe and Mail
CorMedix at Citizens JMP: Strategic Growth and Market Expansion By Investing.com - Investing.com Nigeria
CorMedix at Citizens JMP: Strategic Growth and Market Expansion - Investing.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Just Shipped A Substantial Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Estimates - Yahoo Finance
CorMedix Inc. Reports Strong Q1 Earnings and Positive Outlook - MSN
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates - MSN
(CRMD) Investment Analysis - news.stocktradersdaily.com
CorMedix stock rises after earnings, revenue beat - MSN
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises - Investing.com Nigeria
Cormedix Inc (CRMD) Q1 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ... By GuruFocus - Investing.com Canada
CorMedix Inc. Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises By Investing.com - Investing.com South Africa
CorMedix: Q1 Earnings Snapshot - Norwalk Hour
CorMedix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRMD Price Target Increased as Positive Momentum Builds | CRMD S - GuruFocus
CorMedix Shares Soar After Q1 Earnings, Revenue Beat Consensus - marketscreener.com
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 - The Globe and Mail
Cormedix Inc (CRMD) Q1 2025 Earnings: EPS of $0.32 Beats Estimat - GuruFocus
CorMedix (CRMD) Surpasses Revenue and EPS Expectations in Q1 - GuruFocus
CRMD Price Target Increased as Positive Momentum Builds | CRMD Stock News - GuruFocus
CorMedix Inc. Revises Sales Guidance for the First Half of 2025 - marketscreener.com
CorMedix (CRMD) Surges on Strong Q1 Earnings - GuruFocus
CorMedix Inc (NASDAQ: CRMD): Hidden Gems In A Time Of Volatility - Stocksregister
CRMD Stock Rating and Price Target Maintained by Analyst | CRMD - GuruFocus
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed - Asianet Newsable
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed By Stocktwits - Investing.com India
CorMedix stock rises as Q1 earnings and revenue surpass estimates By Investing.com - Investing.com Nigeria
CorMedix stock rises as Q1 earnings and revenue surpass estimates - Investing.com Australia
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
CorMedix Inc. Reports Q1 2025 Financial Results: $39.1 Million in Net Revenue and Positive Adjusted EBITDA of $23.6 Million - Nasdaq
CorMedix Hits Major Milestone: Reports First Ever Profitable Quarter with $39.1M Revenue, Raises Guidance - Stock Titan
CorMedix Inc (CRMD) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):